Program
AZD6793
A development code.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Diabetes Mellitus, Type 2, led by AstraZeneca.
Furthest: phase 2, since Jun 11, 20255 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 51 open or running | phase 2since Jun 11, 2025 | Nov 16, 2022 | Aug 31, 2027phase 2 · NCT07082738 |
- Named in AstraZeneca’s own pipeline as
AZD6793
, phase 2, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 16, 2022First study: phase 1 study in Inflammatory DiseasesFirst studyNCT05662033 · 93 enrolled · United Kingdom
- Apr 11, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06368440 · 39 enrolled · United States
- Jul 3, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06494644 · 17 enrolled · Germany
- Jun 11, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07082738 · 987 planned · United States, Argentina, Australia and more
- Dec 23, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07433062 · 28 enrolled · Germany
Ahead
- Aug 31, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07082738
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07433062Diabetes Mellitus, Type 2 · Germany | 1 | Suspended | Jun 18, 2026 | 28 |
| NCT07082738Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 2 | Recruiting | Aug 31, 2027 | 987 |
| NCT06494644Pulmonary Disease, Chronic Obstructive · Germany | 1 | Completed | Oct 5, 2024 | 17 |
| NCT06368440Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | Dec 23, 2024 | 39 |
| NCT05662033Inflammatory Diseases · United Kingdom | 1 | Completed | Oct 29, 2024 | 93 |
How it is read
Names in the registry
- “AZD6793”, 6 entries
Codes read as this program: AZD6793.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.